The effect of cyclosporine A in hemorrhagic shock model of rats

The Journal of Trauma and Acute Care Surgery
Kyuseok KimYun-Sik Hong

Abstract

The inhibition of mitochondrial permeability transition pore opening during ischemia-reperfusion can ameliorate injuries. This study aimed to investigate the effects of cyclosporine A (CsA) in rats after hemorrhagic shock. Male Sprague-Dawley rats were subjected to pressure-controlled hemorrhagic shock (mean arterial pressure, 38 ± 1 mm Hg) for 90 minutes. After the hemorrhagic shock period, rats were randomly allocated to one of three groups as follows: a control group, a CsA10 group, or a CsA50 group. CsA for the treatment groups (10 mg/kg for the CsA10 group and 50 mg/kg for the CsA50 group) or normal saline for the control group was administered via tail vein for 10 minutes, and shed blood was transfused for 15 minutes. For the survival study, animals were observed for up to 9 hours, and their survival time was recorded until death. Separate experiments were performed to examine the effect of CsA on inflammatory responses and liver injury. Rats were sacrificed at 210 minutes after the shock period, and blood and liver tissues were harvested. Survival times were shown to be significantly longer in the CsA-treated groups (i.e., the CsA10 and CsA50 groups) than in the control group. Plasma interleukin-6 and thiobarbituric acid...Continue Reading

References

Nov 1, 1985·Kidney International·B M MurrayT F Ferris
Dec 1, 1993·Journal of Molecular and Cellular Cardiology·E J Griffiths, A P Halestrap
Jul 9, 1998·The Journal of Surgical Research·D L TravisM F Levy
May 29, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S J TalerL Schwartz
Mar 7, 2000·Mediators of Inflammation·J E GarcíaJ L Arellano
Sep 15, 2001·Cardiovascular Research·D AltavillaF Squadrito
Feb 7, 2002·Journal of Hepatology·Nina E SaxtonJonathan Fawcett
Nov 6, 2002·Journal of the Neurological Sciences·R Sinigaglia-CoimbraC Coimbra
Feb 9, 2005·Journal of Molecular and Cellular Cardiology·Laurent ArgaudMichel Ovize
Nov 1, 2005·Journal of the American College of Surgeons·Thomas S Helling
May 23, 2006·Surgery Today·M A Tolga MuftuogluAbdullah Saglam
Sep 15, 2007·The New England Journal of Medicine·Derek M Yellon, Derek J Hausenloy
Feb 26, 2010·Cardiovascular Drugs and Therapy·Andreas SkyschallyGerd Heusch
Sep 21, 2010·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Danny RamzyVivek Rao
Nov 23, 2010·Nature Reviews. Immunology·Grace Y Chen, Gabriel Nuñez
Feb 8, 2011·Biochimica Et Biophysica Acta·Fabio Di LisaPaolo Bernardi
May 24, 2011·Cell Calcium·Andrea Rasola, Paolo Bernardi
Dec 18, 2012·Expert Opinion on Investigational Drugs·Xingmin WangKe-seng Zhao
Feb 21, 2014·The Journal of Trauma and Acute Care Surgery·Jae Hyuk LeeHeajin Chung

❮ Previous
Next ❯

Citations

Mar 19, 2016·Molecular BioSystems·Nancy E WitowskiGreg J Beilman
Feb 5, 2021·International Immunopharmacology·Qiuyi GuiLuyong Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.